Esperion Therapeutics, Inc. (ESPR)
After hours:
| Previous Close | 6.36 |
| Open | 6.30 |
| Bid | 6.28 x 3200 |
| Ask | 6.90 x 800 |
| Day's Range | 6.12 - 6.47 |
| 52 Week Range | 3.28 - 20.75 |
| Volume | |
| Avg. Volume | 1,215,716 |
| Market Cap | 406.393M |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.24 |
| Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.80 |
- Zacks
Enanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar?
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- Simply Wall St.
Is Esperion Therapeutics, Inc. (NASDAQ:ESPR) Popular Amongst Institutions?
The big shareholder groups in Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) have power over the company. Insiders often...
- GlobeNewswire
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
– Less than 1 in 10 were on any non-statin lipid lowering therapy – – Findings were shared at the National Lipid Association Scientific Sessions – ANN ARBOR, Mich., June 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced findings from a real-world analysis of more than 400,000 patients at high-risk for atherosclerotic cardiovascular disease (ASCVD). The findings were presented at the National Lipid Association Scientific Sessions in Scottsdale, Arizona. “While professional guidelines
